Inventor · disambiguated record
Ross La Motte-Mohs
Also filed as: LA MOTTE-MOHS ROSS
11 granted patents·6 pending applications·63 citations·filing 2009–2025
89Inventor score
Files withMACROGENICS INC12SUNNYBROOK HEALTH SCIENCES CT2BRISTOL MYERS SQUIBB CO1INCYTE CORP1ZUNIGA-PFLUCKER JUAN CARLOS1
Top patents by PatentIndex Score
17 records- 0195US10577422B2PD-1-binding molecules and methods of use thereofMACROGENICS INC·Filed 2016·Granted Mar 3, 2020·19 cites·10 claims
- 0295US10160806B2Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereofMACROGENICS INC·Filed 2015·Granted Dec 25, 2018·18 cites·34 claims
- 0393US11858991B2LAG-3-binding molecules and methods of use thereofMACROGENICS INC·Filed 2021·Granted Jan 2, 2024·2 cites·18 claims
- 0488US11072653B2LAG-3-binding molecules and methods of use thereofMACROGENICS INC·Filed 2016·Granted Jul 27, 2021·4 cites·17 claims
- 0588US10954301B2Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereofMACROGENICS INC·Filed 2016·Granted Mar 23, 2021·3 cites·8 claims
- 0686US11098119B2Covalently bonded diabodies having immunoreactivity with PD-1 and LAG-3, and methods of use thereofMACROGENICS INC·Filed 2018·Granted Aug 24, 2021·2 cites·14 claims
- 0784US8772028B2CD34+CD7+CD5+CD1a-human progenitor T-cells produced in vitro and methods of usingZUNIGA-PFLUCKER JUAN CARLOS·Filed 2009·Granted Jul 8, 2014·10 cites·9 claims
- 0884US2025304685A1Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereofMACROGENICS INC·Filed 2025·Application pending·0 cites
- 0980US10266805B2Human progenitor T-cells into NK cellsSUNNYBROOK HEALTH SCIENCES CT·Filed 2016·Granted Apr 23, 2019·3 cites·5 claims
- 1080US2024084015A1Methods of using bispecific molecules having immunoreactivity with pd-1 and ctla-4MACROGENICS INC·Filed 2023·Application pending·0 cites
- 1179US9533009B2Producing human CD34+CD7+CD5+CD1a− progenitor T cells and method of treatmentSUNNYBROOK HEALTH SCIENCES CT·Filed 2014·Granted Jan 3, 2017·2 cites·11 claims
- 1274US2022041714A1Covalently Bonded Diabodies Having Immunoreactivity with PD-1 and LAG-3, and Methods of Use ThereofMACROGENICS INC·Filed 2021·Application pending·0 cites
- 1373US11840571B2Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4MACROGENICS INC·Filed 2021·Granted Dec 12, 2023·0 cites·20 claims
- 1453US2023172923A1Methods of treating cytokine-related adverse eventsBRISTOL MYERS SQUIBB CO·Filed 2021·Application pending·0 cites
- 1552US2023056230A1Therapy for the Treatment of CancerMACROGENICS INC·Filed 2020·Application pending·0 cites
- 1649US12448448B2Anti-PD-1 antibodies and uses thereofINCYTE CORP·Filed 2019·Granted Oct 21, 2025·0 cites·6 claims
- 1747US2022213203A1Dosing Regimens of Bispecific CD123 x CD3 Diabodies in the Treatment of Hematologic MalignanciesMACROGENICS INC·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →